PharmaShots | Incisive News in 3 Shots

Subscribe Now

Janssen

Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung Cancer

Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung C...

September 29, 2023

Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC at IASLC 2023 WCLC

Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC...

September 12, 2023

Janssen Reports the MAA Submission of Erdafitinib to the EMA for Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations

Janssen Reports the MAA Submission of Erdafitinib to the EMA for Locally Advanced or Metastatic Urothelial Cancer with Susceptible...

September 8, 2023

Janssen Reports P-III Study (MARIPOSA-2) Results of Rybrevant (amivantamab-vmjw) for EGFR-Mutated Non-Small Cell Lung Cancer

Janssen Reports P-III Study (MARIPOSA-2) Results of Rybrevant (amivantamab-vmjw) for EGFR-Mutated Non-Small Cell Lung Cancer

September 7, 2023

Janssen Reports the sBLA Submission of Rybrevant to the US FDA as 1L Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Janssen Reports the sBLA Submission of Rybrevant to the US FDA as 1L Treatment of Locally Advanced or Metastatic Non-Small Cell Lu...

August 28, 2023

$Janssen’s Talvey (talquetamab) Receives EC’s Conditional Marketing Authorization for the Treatment of Relapsed and Refractory Multiple Myeloma$

Janssen’s Talvey (talquetamab) Receives EC’s Conditional Marketing Authorization for the Treatment of Relapsed and Refractory Mult...

August 22, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us